Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen. Genotyping from 29 nelfinavir failures revealed D30N in 17 (59%) and L90M in 11 (38%) cases. Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus.
Saah
Alfred J
AJ
Merck Research Laboratories, West Point, PA 19486, USA.
Haas
David W
DW
DiNubile
Mark J
MJ
Chen
Joshua
J
Holder
Daniel J
DJ
Rhodes
Rand R
RR
Shivaprakash
Malathi
M
Bakshi
Kalpana K
KK
Danovich
Robert M
RM
Graham
Donald J
DJ
Condra
Jon H
JH
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D024882:Drug Resistance, Viral; D005260:Female; D006678:HIV / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir / Q000494:pharmacology / Q000627:therapeutic use*; D063065:Organophosphonates; D010078:Oxazines / Q000494:pharmacology / Q000627:therapeutic use*; D017211:Treatment Failure
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D010078:Oxazines; D019469:Indinavir; C053001:adefovir; D019888:Nelfinavir; D000225:Adenine; C098320:efavirenz